LUNGevity Foundation Issues Request for Applications for 2019 Career Development Awards for Translational Research in Lung Cancer
WASHINGTON, Jan. 15, 2019 /PRNewswire/ -- LUNGevity has issued a Request for Applications (RFA) for translational research for Career Development Awards that will be granted in 2019. The RFA is available on the LUNGevity website at www.LUNGevity.org/CDA-RFA and is also posted on the proposalCENTRAL website at proposalcentral.altum.com.
LUNGevity's Career Development Awards for Translational Research program was created to support future research leaders who will keep the field of lung cancer research vibrant with new ideas. Since 2002, LUNGevity has funded 127 projects at 59 institutions in 23 states.
Projects that will be funded in 2019 are expected to have a direct impact on the early detection of lung cancer and/or individualized lung cancer treatment, including through targeted therapy and immunotherapy.
Successful applicants may receive $100,000 per year for a possible period of three years and will participate as non-voting members of LUNGevity's Scientific Advisory Board for the duration of the award. Applicants must be within the first five years of their first faculty appointment. The Career Development Awards are mentored awards, and a mentoring plan is part of the required submission.
"Our Career Development Award Program is in its eighth year, and we are excited to solicit yet another round of high-quality research proposals from the next generation of lung cancer researchers. Of the ten past awardees who have graduated from the program, eight have already secured independent federal funding to establish their laboratories and continue their impactful research," noted Dr. Upal Basu Roy, LUNGevity's Senior Director of Research.
Letters of intent must be submitted by Tuesday, February 19, 2019.
About LUNGevity Foundation
LUNGevity is the nation's leading lung cancer organization investing in lifesaving, translational research and providing support services and education for patients and caregivers. LUNGevity's goals are three-fold: (1) accelerate research to patients, (2) empower patients to be active participants in their treatment decisions, and (3) remove barriers that patients face in accessing the right treatments.
LUNGevity Foundation is firmly committed to making an immediate impact on increasing quality of life and survivorship of people with lung cancer by accelerating research into early detection and more effective treatments, as well as by providing community, support, and education for all those affected by the disease. LUNGevity's comprehensive resources include a medically vetted website, a toll-free HELPLine in partnership with CancerCare®, a unique Lung Cancer Navigator app, peer-to-peer mentoring for patients and caregivers (LUNGevity LifeLine), and survivorship conferences. LUNGevity also helps patients find and navigate clinical trials through our Clinical Trial Finder tool, a Clinical Trial Ambassador program, and participation with EmergingMed.
Our vision is a world where no one dies of lung cancer. For more information about LUNGevity Foundation, a four-star Charity Navigator organization, please visit www.LUNGevity.org.
About Lung Cancer in the U.S.
About 1 in 16 Americans will be diagnosed with lung cancer in their lifetime
More than 234,000 people in the U.S. will be diagnosed with lung cancer this year
About 60%-65% of all new lung cancer diagnoses are among people who have never smoked or are former smokers
Lung cancer takes more lives than the next three leading cancers (colorectal, breast, and prostate) combined
Only 19% of all people diagnosed with lung cancer will survive 5 years or more, BUT if it's caught before it spreads, the chance of 5-year survival improves dramatically